Morphic Holding, Inc.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF…
Biotechnology
US, Waltham [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 31.89 | 38.17 | 28.94 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -32.58 | 0.77 | 1.14 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -5.30 | 13.27 | 14.01 | |
| Cash | -6.96 | 13.17 | 14.16 | |
| Capex | -620.94 | -0.01 | < 0.005 | |
| Free Cash Flow | -63.31 | -0.94 | -0.58 | |
| Revenue | inf | 0.00 | -1.21 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | inf | 0.00 | 1.00 | |
| Operating Margin | inf | 0.00 | 0.82 | |
| ROA | -17.67 | -0.07 | -0.06 | |
| ROE | -16.80 | -0.07 | -0.06 | |
| ROIC | -13.57 | -0.08 | -0.07 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of MORF is permitted for members.
5
Growth
The "Growth Entry" for the Focus of MORF is permitted for members.
6
Leverage & Liquidity